Gordon Waldron


Gordon has over 25 years’ experience in high tech, med tech and biotech. During his career, he has raised over €M175 in venture capital funding, over €M50 in an IPO and has been involved in 10 M&A / Exit transactions. Gordon is the Former Vice President and Chief Financial Officer of Novexel, an antibacterial drug discovery company. At Novexel, he participated in a preclinical license negotiation which brought the company a €M75 upfront payment in 2008 and negotiated the sale of Novexel to Astra Zeneca for cash consideration of approximately $500m million in 2009.